These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 23091202

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands.
    Henry TL, De Brouwer BF, Van Keep MM, Blankestijn PJ, Bots ML, Koffijberg H.
    J Med Econ; 2015 Jan; 18(1):76-87. PubMed ID: 25367314
    [Abstract] [Full Text] [Related]

  • 5. Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario.
    Chowdhury EK, Reid CM, Zomer E, Kelly DJ, Liew D.
    Am J Hypertens; 2018 Sep 11; 31(10):1156-1163. PubMed ID: 30010694
    [Abstract] [Full Text] [Related]

  • 6. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY, Ko SK, Liew D.
    Clin Ther; 2009 Dec 11; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [Abstract] [Full Text] [Related]

  • 7. Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension.
    Chung O, Vongpatanasin W, Bonaventura K, Lotan Y, Sohns C, Haverkamp W, Dorenkamp M.
    J Hypertens; 2014 Dec 11; 32(12):2411-21; discussion 2421. PubMed ID: 25255395
    [Abstract] [Full Text] [Related]

  • 8. Orthostatic function after renal sympathetic denervation in patients with resistant hypertension.
    Lenski M, Mahfoud F, Razouk A, Ukena C, Lenski D, Barth C, Linz D, Laufs U, Kindermann I, Böhm M.
    Int J Cardiol; 2013 Nov 30; 169(6):418-24. PubMed ID: 24157238
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.
    Carlson JJ, Hansen RN, Dmochowski RR, Globe DR, Colayco DC, Sullivan SD.
    Clin Ther; 2013 Apr 30; 35(4):414-24. PubMed ID: 23522658
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
    Sanon M, Taylor DC, Parthan A, Coombs J, Paolantonio M, Sasane M.
    J Med Econ; 2013 Apr 30; 16(1):150-9. PubMed ID: 22762291
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
    Boersma C, Gansevoort RT, Pechlivanoglou P, Visser ST, van Toly FF, de Jong-van den Berg LT, de Jong PE, Postma MJ, Prevention of Renal and Vascular End Stage Disease Study Group.
    Clin Ther; 2010 Jun 30; 32(6):1103-21. PubMed ID: 20637965
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.